Business
Cuprina Reaffirms Commitment to Shareholders and Patients Following Recent Stock Market Activity
Singapore, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”) issued the following statement in response to recent unusual trading activity and speculation surrounding the Company. Over the past week, the Company’s stock has experienced heightened trading volatility, which we understand has raised concerns among some shareholders. We want to take this opportunity to reaffirm that Cuprina is a fully operational, legally compliant, and m
About this update from Cuprina Holdings (cayman) Limited
[{"type":"image","alt":"Cuprina Holdings (Cayman) LTD","displaySize":"","headline":null,"caption":"Cuprina Holdings (Cayman) LTD","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":73,"url":"https://media.zenfs.com/en/globenewswire.com/402f43f30f35f5ccdd587985aebd2fe7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Vs5DV_xDy69c4LSgVE319A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwMjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/402f43f30f35f5ccdd587985aebd2fe7","width":300,"height":73}},"lazy":false},{"type":"text","content":"Singapore, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”) issued the following statement in response to recent unusual trading activity and speculation surrounding the Company.","length":241,"tagName":"p"},{"type":"text","content":"Over the past week, the Company’s stock has experienced heightened trading volatility, which we understand has raised concerns among some shareholders. We want to take this opportunity to reaffirm that Cuprina is a fully operational, legally compliant, and mission-driven biotechnology company. We remain focused on advancing our pipeline, expanding access to our biotherapeutic solutions, and delivering long-term value to patients, clinicians, and shareholders alike.","length":469,"tagName":"p"},{"type":"text","content":"“We recognize that some investors have questions following Friday’s unusual trading activity. The Company is not aware of any operational reasons for this stock price volatility nor of any material adverse events which may have led to this activity. Let us be clear: Cuprina is operationally in a healthy position and is diligently executing on its business plan since the Company’s Initial Public Offering earlier this year. We are a Nasdaq-listed company with audited financials, an expanding footprint in Asia and beyond, and a pipeline of regulated medical products serving and benefitting real patients in need. Our team continues to work tirelessly to commercialize breakthrough biologics and scale our global partnerships. While share price volatility is largely outside of our control, execution and transparency remain firmly within it,” said David Quek, Chief Executive Officer and Executive Director of Cuprina.","length":922,"tagName":"p"},{"type":"text","content":"The Company also empha...